ASN Meetings
Am J Clin Nutr (February 3, 2010). doi:10.3945/ajcn.2009.28113
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
91/4/985    most recent
ajcn.2009.28113v1
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lips, P.
Right arrow Articles by Papanicolaou, D. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lips, P.
Right arrow Articles by Papanicolaou, D. A
Agricola
Right arrow Articles by Lips, P.
Right arrow Articles by Papanicolaou, D. A
© 2010 American Society for Clinical Nutrition

Once-weekly dose of 8400 IU vitamin D3 compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency1,2,3

Paul Lips, Neil Binkley, Michael Pfeifer, Robert Recker, Suvajit Samanta, Dosinda A Cohn, Julie Chandler, Elizabeth Rosenberg and Dimitris A Papanicolaou

1 From the Department of Endocrinology Vrije Universiteit Medisch Centrum Amsterdam Netherlands (PL); the Department of Osteoporosis Clinical Research University of Wisconsin Madison WI (NB); Klinik der Furstenhof Bad Pyrmont Germany (MP); the Osteoporosis Research Center Creighton University Omaha NE (RR); Merck & Co Inc Rahway NJ (SS DAC JCDAP);Merck & Co Inc North Wales PA (ER).

2 Supported by Merck & Co Inc.

3 Address correspondence to P Lips, Department of Endocrinology, Vrije Universiteit Medisch Centrum, PO Box 7057, Amsterdam 1007 MB, Netherlands. E-mail: p.lips{at}vumc.nl.

ABSTRACT

Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls.

Objective: We examined the effects of a weekly dose of 8400 IU vitamin D3 on postural stability, muscle strength, and safety.

Design: In this double-blind trial, subjects aged ≥70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations ≤20 but ≥6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D3 (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSwayPLUS platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored.

Results: Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P < 0.001) in patients treated with 8400 IU vitamin D3 but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (≥0.46 compared with <0.46 cm), treatment with 8400 IU vitamin D3 significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D3, but not in placebo-treated patients, the parathyroid hormone decreased significantly.

Conclusions: Weekly treatment with 8400 IU vitamin D3 raised 25(OH)D concentrations in elderly, vitamin D–insufficient individuals. Treatment with 8400 IU vitamin D3 did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D3 reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D3 was well tolerated. This trial was registered at clinicaltrials.gov as NCT00242476.

Received for publication May 21, 2009. Accepted for publication January 8, 2010.